Barclays Believes NUVA Won’t Stop Here

Barclays analyst Matthew Taylor maintained a Buy rating on NuVasive (NASDAQ: NUVA) today and set a price target of $74. The company’s shares closed last Friday at $67.21, close to its 52-week high of $69.

According to TipRanks.com, Taylor is a 4-star analyst with an average return of 6.7% and a 68.8% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Zimmer Biomet Holdings, and Baxter International.

NuVasive has an analyst consensus of Strong Buy, with a price target consensus of $72.29.

The company has a one year high of $69 and a one year low of $36.81. Currently, NuVasive has an average volume of 603.4K.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NUVA in relation to earlier this year. Most recently, in June 2015, Jack Blair, a a Director at NUVA sold 6,000 shares for a total of $299,720.

NuVasive, Inc. engages in the provision of medical devices. It involves in the manufacture, development and sale of minimally-disruptive surgical products to treat the spine problems including spinal cord as well as cervical spine. IT offers cervical fusion surgery, spine fusion surgery, cervical plating and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.